Author:
Vergnenègre A.,Daniel C.,Léna H.,Fournel P.,Kleisbauer J.P.,Caer H. Le,Letreut J.,Paillotin D.,Pérol M.,Bouchaert E.,Preux P.M.,Robinet G.
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference32 articles.
1. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on 16 May 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996–3018.
2. Standards, options and recommendations for the management of locally advanced non-small-cell lung carcinoma;Bardet;Bull Cancer,2001
3. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer;Atagi;Lung Cancer,2002
4. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group. Phase II study, SWOG 9019;Albain;J Clin Oncol,2002
5. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999